INCREASED NUCHAL TRANSLUCENCY

Yes, the level of increased nuchal translucency impacts your baby’s health outcomes.

NT thickness levels and the chances of having a healthy baby (%)

• normal NT <95th centile – 97%
• 95th-99th centile – 93%
• 3.5-4.4mm – 70%
• 4.5-5.4mm – 50%
• 5.5-6.4mm – 30%
• >6.5mm – 15%

Those are the results of a landmark study led by Prof Nicolaides and his team from King’s College Hospital in 2005, titled “Increased nuchal translucency with normal karyotype,” which sheds light on how NT measurement matters during pregnancy.

This research uncovers a strong connection between a higher NT measurement and potential challenges in your pregnancy journey. These challenges can include chromosomal defects, the possibility of significant fetal anomalies (including heart defects) and a slightly increased risk of miscarriage and fetal loss. 

A crucial takeaway from this study is the inverse relationship between NT thickness and the likelihood of experiencing a complication-free pregnancy with a healthy baby. As the NT measurement increases, the likelihood of a smooth pregnancy with a healthy baby may decrease.

If nuchal translucency range is 6.5mm or more the chances of delivering a healthy baby are only 15%. It means that only one in 7 babies with very high NT will be completely healthy.

2.5 mm is the highest value of normal NT at 12 weeks of gestation. NT levels from 2.6 mm are >95th centile for this gestational age (increased NT).

2.7 mm is the highest value of normal NT at 12 weeks of gestation. NT ranges from 2.8 mm are equal to or above the 95th centile for this stage of pregnancy (increased NT).

NT measuring 3.0mm at 12 weeks indicates a slightly increased measurement, placing it between the 95th and 99th centiles. While this increase suggests a slight rise in the chances of chromosomal, genetic, cardiac, or structural problems, it’s important to note that 93% of babies within this range will be born healthy, and only 7% will have issues. If your CST results are low chance (less than 1 in 150), the NHS might not offer you additional tests.

To provide peace of mind and a more comprehensive evaluation, our recommendation is to consider the SMART TEST. The SMART TEST is a comprehensive screening program designed to assess the health and development of your baby during pregnancy. It includes:

Advanced Ultrasound Scans: Our experts will perform early anomaly scans to evaluate various aspects of your baby’s anatomy. This includes detailed assessments of the head, face, heart, abdomen, and other vital structures.

Early Fetal Echocardiography: This specialized ultrasound examination focuses on your baby’s heart, helping to detect any potential cardiac issues early in pregnancy.

NIPT for Chromosomal Anomalies, Microdeletions and Monogenic Conditions (PrenatalSafe Complete Plus): Our SMART TEST features advanced non-invasive prenatal testing (NIPT) that checks also for monogenic disorders, which are single-gene diseases like Noonan syndrome.

The SMART TEST aims to offer you the utmost reassurance and comprehensive insights into your baby’s health, allowing for early detection and timely management of potential issues.

We are truly sorry to inform you that your baby’s NT measurement, which is 6.6mm at 13 weeks, falls within a very high range. Based on clinical evidence, the likelihood of delivering a healthy baby in this situation is only 15-20%. Many babies with such an NT thickness may have chromosomal, genetic, cardiac, or structural issues.

In this challenging situation, our recommendation is to proceed with an Early Fetal Echocardiography, which includes Early Fetal Scan, and to consider the NHS option of CVS (chorionic villus sampling). Additionally, you may qualify for the rapid exome (R21) study, which you can learn more about in our Q&A section.

Another alternative to consider is the SMART TEST, which offers a comprehensive evaluation. Please don’t hesitate to contact us for further information and support.

The optimal scan for a baby with increased nuchal translucency is the Early Fetal Echocardiography, available at our London Pregnancy Clinic starting from 12 weeks. It’s performed alongside an early anomaly scan. These scans serve to rule out most heart defects contributing to increased NT, as well as structural anomalies like exomphalos associated with raised NT. We believe in avoiding any delay and suggest these scans be conducted as soon as possible, ideally before CVS.

While a normal Nuchal Translucency (NT) measurement is reassuring, it’s essential to understand that it doesn’t guarantee protection against serious problems or diseases. Some conditions, like as anencephaly (a severe brain defect), holoprosencephaly (another brain abnormality), gastroschisis (a defect in the abdominal wall), renal abnormalities, and spina bifida (a neural tube defect), can still occur at the same rates as in the general population, even if the NT is normal.

Also, it is important to know that more than half of severe heart defects can appear in babies with normal NT measurements.

That is a valid point indeed. We often discuss increased or elevated nuchal translucency (NT), but what if the NT is low? Does a lower NT pose any risks to the baby or the pregnancy? Is a very low NT (less than 5th centile) considered abnormal?

Here’s a reassuring answer: A low nuchal translucency measurement is not associated with any adverse outcomes for the baby or the pregnancy. In other words, it doesn’t matter how low the NT measurement is. In practical terms, when low NT measurements are factored into Combined Screening Test (CST) calculations, they lead to lower probabilities for conditions like Down’s syndrome and other chromosomal problems.

So, low nuchal translucency levels (NT numbers of around one mm) are brilliant news for you and your baby.

Our response to the frequently asked question, “Is nuchal translucency 1.2 mm at 12 weeks normal?” is a resounding “Yes, it is unquestionably normal!”

The two blood tests, Combined Screening Test (CST) and Non-Invasive Prenatal Testing (NIPT) serve different purposes in Down syndrome screening.

CST, a traditional blood test, measures specific proteins in the mother’s blood—PAPP-A (pregnancy-associated plasma protein-A) and hCG (human chorionic gonadotropin). This test evaluates the likelihood of the fetus having Down syndrome and other chromosomal abnormalities.

On the other hand, NIPT, which stands for Non-Invasive Prenatal Testing, is a more advanced blood test. It detects fetal cell-free DNA present in the mother’s blood, offering a highly accurate assessment of the risk for chromosomal conditions like Down syndrome. Unlike CST, NIPT involves analyzing the fetal DNA fragments circulating in the maternal bloodstream, providing a more detailed and accurate insight into the baby’s genetic health.

NIPT can be performed earlier in pregnancy, typically from around 10 weeks, whereas CST (Combined Screening Test) is conducted later, at 11-13 weeks. The early timing of NIPT allows for earlier insights into the baby’s genetic health, which can be advantageous for expectant parents who seek to obtain information about chromosomal conditions like Down syndrome at an earlier stage in their pregnancy.

The NHS implements “nuchal translucency screening” in two primary ways.

Firstly, it is a component of the Combined Screening Test (CST), where the nuchal translucency (NT) measurement is one of several variables used to assess the risk for chromosomal conditions in the baby.

Secondly, an absolute NT measurement of 3.5mm or more is considered an abnormal value. In this case, it leads to further referral to the Fetal Medicine Unit (FMU) for more extensive evaluation and potentially a chorionic villus sampling (CVS) test to assess the baby’s health.

This approach aims to ensure a thorough assessment and timely intervention if required for the well-being of the baby.

The topic of Nuchal Translucency (NT) is highly significant within the medical field, with approximately 3,000 clinical research publications dedicated to this subject, according to the PubMed database.

Noonan syndrome is a genetic condition strongly associated with increased NT. Noonan syndrome is a monogenic disease (single-gene disorder) and cannot be identified through the current CVS or amniocentesis methods. These tests examine chromosomes using PCR or detect microdeletions through microarrays, unable to identify genetic single-gene disorders. In some instances, material obtained from CVS can undergo an additional check using rapid exome(R21 in the NHS England National Genomic Test Directory). Please refer to the details in the Q&A below.

Alternatively if you wish to undergo a test for Noonan syndrome, but your situation does not meet the R21 eligibility criteria, the SMART TEST is a valuable option. The SMART TEST not only checks for most Noonan Syndrome mutations but can also detect ultrasound features associated with Noonan syndrome.

Rapid prenatal exome sequencing (R21 in the NHS England National Genomic Test Directory) is a specialized genetic test that is conducted in certain high-risk pregnancies where a genetic diagnosis can be incredibly helpful in guiding how the pregnancy is managed.

Currently, at NHS, the R21 test can only be requested by a consultant clinical geneticist after discussing the situation with the local obstetrics team. This test is performed on samples taken during specific prenatal procedures like CVS (Chorionic Villus Sampling) or amniocentesis. The focus of this test is to examine a predetermined panel of genes that are known to be associated with disorders that can become apparent before birth. R21 testing is based on a technology called exome sequencing, which examines a wide range of genes.

In terms of Nuchal Translucency (NT) measurement, R21 testing might be recommended when a fetus shows:

1. A Nuchal Translucency measurement greater than 6.5 millimeters.
2. The presence of at least one additional anomaly or unusual finding.
3. When results from CVS or amniocentesis (PCR and arrays), which are other genetic tests, come back as normal.

It’s important to note that this test examines a specific set of genes, and it is particularly useful for identifying monogenic disorders such as Noonan syndrome. As information about this testing may change over time, it’s a good idea to check for updates in GeNotes when you need the most current information.

Exome sequencing is a valuable genetic testing method that focuses on analyzing the exome, which contains the protein-coding genes in the human genome. These genes provide instructions for building the proteins necessary for various biological functions. Exome sequencing allows for a thorough examination of the exome to identify variations or mutations in the genes that may be responsible for genetic disorders or health conditions.

Exome sequencing can be particularly useful in cases of raised NT during pregnancy. This is because it enables a comprehensive analysis of a wide range of genes associated with genetic disorders. When a fetus presents with an increased NT measurement, it may suggest an underlying genetic issue. Exome sequencing can help identify potential genetic mutations or variations that might contribute to the raised NT.

By examining the exome, clinicians and geneticists can pinpoint genetic mutations that could be associated with conditions such as Noonan syndrome, which is one of the genetic disorders strongly linked to increased NT. Therefore, exome sequencing can provide valuable insights into the genetic factors associated with increased NT measurement, allowing for more accurate diagnosis and personalized management of the condition.

Exome Test:

• Diagnostic Genetic Test: The exome test is a diagnostic genetic test that analyzes the exome, which is the part of your DNA responsible for encoding proteins. It’s an invasive test, typically performed through procedures like CVS or amniocentesis.
• Checks Genotype without Phenotype: The exome test focuses on identifying genetic variations (genotype) that may cause specific genetic disorders. It does not evaluate the physical characteristics or anomalies (phenotype) of the baby.
• Invasive: This test involves a needle procedure that carries a small risk of miscarriage.
• No Anomaly Assessment: The exome test does not include the assessment of structural anomalies or physical abnormalities in the baby.

SMART TEST:

• Holistic Approach: The SMART TEST is a comprehensive screening approach that checks both the physical characteristics (anomalies or phenotype) and genetic variations (genotype) in your baby.
• Selected Monogenic Disorders: It assesses specific monogenic disorders, such as Noonan syndrome, as part of its genetic evaluation. SMART TEST encompasses advanced NIPT, which screens for the most prevalent mutations associated with specific syndromes. It’s essential to know that this test may not identify rare genetic variants (mutations) and can potentially yield false-negative results. Therefore, while it provides valuable insights and information, it may not cover every possible genetic variation.
• Non-Invasive: The SMART TEST is a non-invasive test that uses advanced ultrasound scans and NIPT to evaluate the baby’s health. It does not involve needles and is safer for the pregnancy.
• Probabilities: Instead of providing a definitive diagnosis, the SMART TEST offers probabilities or chances of certain conditions.

In summary, the exome test is a diagnostic genetic test focusing on genotype. At the same time, the SMART TEST takes a holistic approach, checking both genotype and phenotype and is non-invasive, making it a safer and more comprehensive early pregnancy option for many expectant parents. However, the SMART TEST provides probabilities rather than definitive diagnoses, and the number of genetic conditions it currently checks is still limited.

If you’ve had a diagnostic CVS, you might still consider NIPT for monogenic disorders for a broader range of genetic testing.

The SMART TEST is a comprehensive screening option that checks for monogenic disorders, which typical CVS cannot detect. It includes structural assessment of the baby along with fetal echocardiography to exclude congenital heart defects (CHD).

The term “Nuchal test” can be misleading, as it may not specify whether it refers to “nuchal translucency” or “nuchal fold,” which are two distinct measurements in prenatal screening. We believe that, in common usage, the term “nuchal test” often refers to “nuchal translucency.”

When discussing pregnancy and prenatal screenings, it’s crucial to distinguish between different tests and measurements for the well-being of the baby. “Nuchal translucency” and “nuchal fold” are two separate assessments that doctors use during early pregnancy, and they’re not the same thing.

The “nuchal translucency” measurement is obtained through an ultrasound. It involves checking the clear space at the back of the baby’s neck. This test is often conducted around the 11th to 14th week of pregnancy and helps screen for certain chromosomal abnormalities, such as Down syndrome.

On the other hand, the “nuchal fold” measurement is also part of an ultrasound examination. It focuses on the thickness of the tissue at the back of the baby’s neck. Although it’s related to the nuchal translucency assessment, it’s a different measurement that might be used in certain cases and at different stages of pregnancy for various diagnostic purposes.

The term “Nuchal test” might create confusion because it doesn’t specify which of these measurements it refers to—nuchal translucency or nuchal fold. To avoid misunderstandings, it’s best to use the exact and specific terminology when discussing these prenatal screenings. Clarity in communication is essential, especially in the medical field, to ensure everyone understands the exact test being conducted and its implications for the pregnancy.

The term “nuchal fold translucency test” can be confusing due to its mix of terminology, making it potentially unclear in its description. To provide a clear distinction, it’s essential to understand the differences between nuchal translucency (NT) and nuchal fold (NF).

Nuchal Translucency (NT):

• NT is a measurement taken during the first trimester ultrasound scan, typically between 11 and 14 weeks of pregnancy.
• It specifically measures the thickness of the translucent space at the back of the baby’s neck.
• NT is commonly used as a screening tool for chromosomal abnormalities, especially Down syndrome.
• A thicker NT measurement may indicate an increased risk of certain fetal conditions.

Nuchal Fold (NF):

• NF measurement is typically done during the second trimester ultrasound scan, usually between 16 and 24 weeks of pregnancy.
• NF measures the thickness of the nuchal fold at the back of the baby’s neck.
• This measurement is often used to assess the development of the baby and may be a part of the overall evaluation of fetal health.
• NF measurement is different from NT, both in terms of when it’s performed and what it assesses.

So, it’s important to clarify the specific measurement and purpose when discussing this test.

Nuchal Translucency (NT) and Nuchal Fold (NF) represent two separate ultrasound measurements conducted during different stages of pregnancy: NT is typically measured in the first trimester, while NF is assessed in the second trimester. Here’s a detailed comparison of these two measurements:

Gestational Age:

• Nuchal Translucency (NT): Typically measured between 11 and 13 weeks of gestation.
• Nuchal Fold (NF): Usually assessed between 16 and 24 weeks of gestation.

Localization of the finding:

• Nuchal Translucency (NT): Measurement of the clear or translucent space at the back of the fetal neck.
• Nuchal Fold (NF): The thickness or fold of skin at the back of the fetal neck.

Value of Measurements:

• Nuchal Translucency (NT): Considered normal if below the 95th centile for gestational age.
• Nuchal Fold (NF): Considered normal if under 5mm between 16-18 weeks or under 6mm between 18-24 weeks.

Associations:

• Nuchal Translucency (NT): An increased NT measurement is associated with a higher risk of Down syndrome and other chromosomal abnormalities.
• Nuchal Fold (NF): An increased thickness may also be linked to aneuploidy and other fetal abnormalities.

Clinical Use:

• Nuchal Translucency (NT): Primarily utilized for Combined Screening Test (CST) to assess the chance of chromosomal disorders like Down syndrome.
• Nuchal Fold (NF): Although observed during routine ultrasounds, the nuchal fold isn’t specifically used for exact probability calculation, unlike NT.

While there are no specific studies directly comparing NT and nuchal fold for the detection of Down syndrome, NT is widely considered to be a more clinically valuable measurement for assessing the risk of Down syndrome. This is because NT measurements have demonstrated reasonable specificity and sensitivity in numerous clinical settings. Nevertheless, the specific performance of NT and nuchal fold may vary among different healthcare providers and regions. The NT measurement is often preferred due to its established reliability and effectiveness in identifying potential risk factors for Down syndrome.

Cystic hygroma is a fluid-filled sac(s) or cyst(s) that typically develops in the neck or head area of a developing fetus during pregnancy. It is a congenital condition caused by a blockage in the development of the lymphatic system. This results in the accumulation of fluid within the cyst(s), leading to the characteristic appearance of a swelling or lump in the affected area.

Conditions associated with cystic hygroma can include:

• Chromosomal Abnormalities: Cystic hygroma may be associated with chromosomal disorders such as Turner syndrome or trisomies.
• Genetic disorders: Cystic hygroma can be linked to genetic conditions, including Noonan Syndrome.
• Heart Defects: Fetal heart abnormalities can sometimes be linked to cystic hygroma.
• Lymphatic System Disorders: The presence of a cystic hygroma can indicate issues with the development of the lymphatic system, which may lead to lymphedema.
• Other Structural Anomalies: It is possible for cystic hygroma to co-occur with other structural anomalies in the fetus.

It’s crucial to emphasize that discovering cystic hygroma during pregnancy should lead to a thorough evaluation and testing to investigate potential underlying conditions. This may include a specialized anomaly scan, fetal echocardiography, and usually invasive genetic tests.

Skin oedema, also referred to as skin swelling, differs from nuchal translucency (NT). Fetal skin oedema typically indicates a more severe condition. NT is the specific measurement of skin oedema at the back of the fetal neck. Skin oedema involves swelling that can extend to areas like the face, head, chest, and abdomen. This swelling can either be confined to a specific area or spread throughout the body. Generally, when skin oedema is present, the baby might have a serious problem.

Fetal hydrops refers to an abnormal accumulation of fluid in two or more body areas of the fetus. This condition results from various reasons, leading to excessive fluid build-up in spaces like the abdomen, chest, or under the skin. 

Although it is not very common, it is possible for a baby at 11-13 weeks to develop hydrops. Unfortunately, first-trimester hydrops often result in a poor outcome for the baby.

Early fetal hydrops is strongly associated with several conditions, such as trisomy 21 (Down syndrome), 45X (Turner syndrome), trisomy 18 (Edwards syndrome), Noonan syndrome, and fetal akinesia deformation sequence, among other causes.

Yes, fluid can be present inside the baby at 11-13 weeks of pregnancy. This is different from increased NT, as the latter specifically measures fluid under the skin at the back of the fetal neck. In cases of fetal hydrops, fluid accumulates in two or more different areas of the baby’s body.

These areas may include around the lungs, known as pleural effusion, around the heart, called pericardial effusion, or inside the abdominal cavity, referred to as ascites. Typically, babies with fetal hydrops also have increased NT measurements.

It’s essential to underscore that detecting fluid in any part of the baby’s body during the first trimester of pregnancy should trigger a comprehensive assessment and testing to explore potential underlying conditions. This assessment may involve a specialized early fetal scan, early fetal echocardiography, and typically CVS (chorionic villus sampling).

Cystic hygroma and nuchal translucency (NT) are distinct from each other. NT refers to a fluid-filled space typically observed behind the fetal neck during a first-trimester ultrasound. Unlike cystic hygroma, NT is considered a normal structure when its measurement falls within the typical range.

The key differences between cystic hygroma and nuchal translucency (NT) are as follows:

Location: Cystic hygroma is typically located around the neck or head region of the fetus, while NT refers to the measurement of fluid specifically at the back of the fetal neck during an ultrasound scan.

Nature: Cystic hygroma is a physical abnormality characterized by a fluid-filled cyst(s), while NT is a measurement of the thickness of the fluid in the nuchal region.

Diagnostic Significance: Cystic hygroma is often identified during prenatal ultrasound and may indicate an increased risk of chromosomal or genetic abnormalities or other fetal conditions. NT measurement is used to assess the risk of certain chromosomal abnormalities, such as Down syndrome.

It’s important to understand that the current version of SMART TEST, which includes GeneSafe or PrenatalSafe Complete Plus by Eurofins, has one of the most comprehensive monogenic NIPT panels available. However, it may not cover all genetic conditions associated with an increased NT. This limitation arises from the constraints of current genomic technology and the variability of mutations, as well as the constant discovery of new genes related to specific conditions.

Here are a few examples of conditions that may not be detectable by SMART TEST:

Spinal Muscular Atrophy (SMA): SMA is a well-known condition associated with an increased NT. However, GeneSafe cannot screen for SMA. To check for this condition, you can add the UNITY Carrier Screen (another type of sgNIPT), which includes SMA in its assessment.

New or Rare Mutations in Noonan Syndrome: Noonan syndrome can result from mutations in various genes. While GeneSafe covers the majority of pathogenic variants, it may not include all of them. For instance, newly described and rare LZTR1 mutations are not included in the panel.

Conditions like Kabuki Syndrome: Some genetic conditions, such as Kabuki Syndrome, are not part of single-gene NIPT panels. While GeneSafe can not identify mutations in genes like KMT2D and KDM6A, which can cause Kabuki syndrome. SMART TEST can reveal fetal anomalies, including heart defects and other issues, through the Early Fetal Echocardiography and Early Fetal Scan included in the test. However, the specific genetic cause of the fetal condition will remain undiscovered by NIPT.

To address these limitations of single-gene NIPT, it’s possible to consider an exome test on fetal DNA obtained from an invasive sample (as discussed in the Q&A on exome – R21). This way, you can explore a broader spectrum of genetic information and make more informed decisions about your pregnancy. 

Please be aware that the London Pregnancy Clinic specializes in non-invasive fetal testing, which includes ultrasound scans and NIPT. We do not conduct invasive procedures like CVS or amniocentesis. However, if you require invasive testing, we can provide referrals to other healthcare providers in London who offer these services. Your care and well-being during your pregnancy are our top priorities, and we are here to assist you in finding the most appropriate resources for your specific needs.

Yes, it works. Since the early 1990s, medical experts have recognized the significance of NT measurements at 10 weeks. Recent studies have not only reaffirmed this importance but have also highlighted the strong link between increased NT at 10 weeks and conditions like Down’s syndrome and other chromosomal anomalies.

Keep in mind that at 10 weeks, the baby is much smaller compared to the 11-14-week period. Therefore, specific NT range charts have been developed for 9-11 weeks, and these early NT thickness ranges are included in our 95th centile chart. It’s important to note that, for a significant number of healthy babies, increased NT at 10 weeks will naturally resolve, and subsequent scans at 11-13 weeks may show absolutely normal measurements. In these cases, if the results of genetic testing like NIPT or CVS are normal, the outlook for the baby is typically good.

At the London Pregnancy Clinic, our experienced clinicians assess the appearance of NT during the 10-Week Scan. If they observe increased NT, they will measure it and comment in the report if the measurements exceed the 95th percentile. This information is invaluable for parents, primarily because diagnostic tests like CVS can only be performed from 11 weeks onwards, and at this early stage, only NIPT is available. Our fast-track NIPT can provide essential insights into the most common chromosomal anomalies associated with increased NT, including Down syndrome (T21), Edwards syndrome (T18), Patau syndrome (T13), and Turner syndrome (45X). This early information can be a crucial step in ensuring your baby’s well-being.

You can learn more from our dedicated page Nuchal Translucency at 10 weeks.

Nuchal translucency (NT) refers to measuring the clear space at the back of the baby’s neck during the first trimester of pregnancy. The terms mentioned: increased NT, high NT, elevated NT, thickened NT, NT above the range, and abnormal NT—are often used interchangeably. However, they might convey slightly different nuances in context:

• Increased NT: Indicates a measurement that is higher than what is considered typical for the gestational age of the fetus, usually 95th centile.
  
• High NT: Suggests a measurement that exceeds the normal or average range for that stage of the pregnancy; it is unclear if it is 95th or 99th centile.
  
• Elevated NT: Similar to “increased” or “high,” referring to a measurement outside the expected range (>95th centile).
  
• Thickened NT: Another way of describing an NT measurement that is larger than the norm for that stage of pregnancy. Sometimes, 3.0mm is used as a cut-off. We do not recommend using this term and range.
  
• NT above the range: Denotes a measurement that surpasses the established normal range for that specific gestational period, which can be 95th or 99th centiles.
  
• Abnormal NT: Generally refers to an NT measurement that is not within the expected or standard range for that stage of pregnancy. We believe that this term must be reserved to NT 3.5mm or more (>99th centile).

While these terms may be used somewhat interchangeably, they all indicate the same fundamental issue: an NT measurement that is not within the normal range for the gestational age (>95th or >99th centiles). NT thickness of 3.5mm and more represents an abnormal range.

“Transnuchal scan” is not a widely recognized or commonly used term in medical terminology. The combination of the words “Transnuchal Scan” seems to be a blend of “trans” (indicating translucency) and “nuchal.” This suggests that it might have been coined to describe nuchal translucency.

The term “Transnuchal Scan” can be misleading because it doesn’t specify whether it’s referring to nuchal translucency or nuchal fold measurements, which are different. To avoid confusion, it’s best to use the specific terms “Nuchal Translucency (NT) scan” for the clear space at the back of a baby’s neck or “Nuchal Fold scan” for the measurement of the skin fold at a slightly different location during prenatal screenings.

“Lucency” in medical terms refers to a clear or translucent area often seen in X-ray images created by radiography. It’s not commonly used in ultrasound imaging. The term “nuchal lucency” isn’t precisely accurate when discussing prenatal ultrasound. Instead, healthcare professionals use the term “Nuchal Translucency” (NT) to refer to the clear space at the back of a baby’s neck visible during an ultrasound in early pregnancy.

“Nuchal Translucency” specifically describes the clear space seen in an ultrasound, and it’s a crucial measurement to screen for certain conditions. It’s important for parents to be aware of this term and its significance during early pregnancy screenings, as it provides valuable information about the baby’s health.

Therefore, the term “nuchal lucency” is not a correct or commonly used expression. Using “nuchal lucency” might cause confusion as it doesn’t accurately represent the intended meaning and could lead to misunderstandings. Therefore, it’s recommended to stick to the established term “Nuchal Translucency” to avoid any confusion and ensure clear communication between healthcare providers and parents.

Many internet searches for “nuclear translucency” are the result of smartphone autocorrection, which actually refers to “nuchal translucency.” If your smartphone’s autocorrect has brought you here, you’ve landed in the right place. This page is dedicated to NT and its significance for your baby’s well-being. It’s important to note that there’s nothing “nuclear” about nuchal translucency. However, in some unfortunate cases, the severity of the news associated with NT findings can be so impactful that it may feel like a “nuclear” event for parents.